Comparison of the PRNT and an immune fluorescence assay in yellow fever vaccinees receiving immunosuppressive medication

Wieten, Rosanne W.; Jonker, Emile F.F.; Pieren, Daan K. J.; Hodiamont, Caspar J.; Thiel, Pieter P. A. M. van; Gorp, Eric C. M. Van; Visser, Adriëtte W. de; Grobusch, Martin P.; Visser, Leo G.; Goorhuis, Abraham

doi:10.1016/j.vaccine.2016.01.037

Cited by 22 publications

(25 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent case report9 described immune-protective YF antibodies 2 years after YFV in a 63-year-old woman with Crohn's disease, who had inadvertently received the YFV while receiving adalimumab therapy. Furthermore, a study among a Dutch group of 15 immunocompromised travellers (most of whom received MTX) found protective levels of YF antibodies a median of 33 days after primary YF vaccination 10. Like our patient, no SAEs were observed in these studies.…”

Section: Discussionsupporting

confidence: 69%

Inadvertent yellow fever vaccination of a patient with Crohn's disease treated with infliximab and methotrexate

et al. 2016

View full text Add to dashboard Cite

We present a case of a 56-year-old woman with Crohn's disease, treated with methotrexate and infliximab, who inadvertently received yellow fever vaccination (YFV) prior to a journey to Tanzania. She was not previously vaccinated against YF. YFV contains live-attenuated virus, and is contraindicated in patients treated with immunosuppressive drugs. Following vaccination, the patient fell ill with influenza-like illness. Elevated transaminase levels and YF viremia were detected. Despite being immunocompromised, the patient did not develop more severe adverse effects. Neutralising antibodies to YF virus were detected on day 14 following vaccination and remained protective at least 10 months after vaccination. Limited data is available on outcomes of YFV in patients receiving immunosuppressive therapy, including biologics, and we report this case as a reminder of vigilance of vaccine recommendations in this population.

show abstract

Section: Discussionsupporting

confidence: 69%

Inadvertent yellow fever vaccination of a patient with Crohn's disease treated with infliximab and methotrexate

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The participants were subjects who had received the YFV despite a diagnosis of CIMID and no SAE was reported. There was no difference in AEFV occurrence between patients and healthy individuals [35,[41][42][43][44][45][46][47][48].…”

Section: Studies Selected and Data Extractedmentioning

confidence: 99%

“…Three studies [21,42,48] did not include randomly selected controls and the vaccinated group was not homogeneous, with very different sample sizes in the control group and intervention group. Only one study (Scheinberg 2010) included randomly selected controls and included a homogeneous sample [44].…”

Section: Studies Selected and Data Extractedmentioning

confidence: 99%

“…Five observational studies [41,42,44,45,48] evaluated the neutralizing antibodies to YFV in 180 patients with CIMID using immunosuppressant drugs, including corticosteroids, synthetic or biological. The authors concluded that all immunocompromised patients were able to develop a protective response to the yellow fever booster.…”

Section: Studies Selected and Data Extractedmentioning

confidence: 99%

“…Neutralizing antibodies were measured by PRNT, and an analysis of PBMC (peripheral blood mononuclear cells) and T cells as well as analysis of the cytokine profile produced by CD8+ lymphocytes specific for the yellow fever virus were performed. The results were compared to a control group composed of 41 healthy individuals who were matched for age, sex, and time of vaccination [41,42].…”

Section: Studies Selected and Data Extractedmentioning

confidence: 99%

See 2 more Smart Citations

Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases

et al. 2019

View full text Add to dashboard Cite

Background: In Brazil, we are facing an alarming epidemic scenario of Yellow fever (YF), which is reaching the most populous areas of the country in unvaccinated people. Vaccination is the only effective tool to prevent YF. In special situations, such as patients with chronic immune-mediated inflammatory diseases (CIMID), undergoing immunosuppressive therapy, as a higher risk of severe adverse events may occur, assessment of the risk-benefit ratio of the yellow fever vaccine (YFV) should be performed on an individual level. Main body of the abstract: Faced with the scarcity of specific orientation on YFV for this special group of patients, the Brazilian Rheumatology Society (BRS) endorsed a project aiming the development of individualized YFV recommendations for patients with CIMID, guided by questions addressed by both medical professionals and patients, followed an internationally validated methodology (GIN-McMaster Guideline Development). Firstly, a systematic review was carried out and an expert panel formed to take part of the decision process, comprising BRS clinical practitioners, as well as individuals from the Brazilian Dermatology Society (BDS), Brazilian Inflammatory Bowel Diseases Study Group (GEDIIB), and specialists on infectious diseases and vaccination (from Tropical Medicine, Infectious Diseases and Immunizations National Societies); in addition, two representatives of patient groups were included as members of the panel. When the quality of the evidence was low or there was a lack of evidence to determine the recommendations, the decisions were based on the expert opinion panel and a Delphi approach was performed. A recommendation was accepted upon achieving ≥80% agreement among the panel, including the patient representatives. As a result, eight recommendations were developed regarding the (Continued on next page)

show abstract

2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases

Bass

Chakravarty

Akl

et al. 2023

Arthritis Care & Research

View full text Add to dashboard Cite

To provide evidence-based recommendations on the use of vaccinations in children and adults with rheumatic and musculoskeletal diseases (RMDs).Methods. This guideline follows American College of Rheumatology (ACR) policy guiding management of conflicts of interest and disclosures and the ACR guideline development process, which includes the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. It also adheres to the Appraisal of Guidelines for Research and Evaluation (AGREE) criteria. A core leadership team consisting of adult and pediatric rheumatologists and a guideline methodologist drafted clinical population, intervention, comparator, outcomes (PICO) questions. A review team performed a systematic literature review for the PICO questions, graded the quality of evidence, and produced an evidence report. An expert Voting Panel reviewed the evidence and formulated recommendations. The panel Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to the recommendations within this guideline to be voluntary, with the ultimate determination regarding their application to be made by the clinician in light of each patient's individual circumstances. Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed and endorsed by the ACR are subject to periodic revision as warranted by the evolution of medical knowledge, technology, and practice. ACR recommendations are not intended to dictate payment or insurance decisions, and drug formularies or other third-party analyses that cite ACR guidelines should state this. These recommendations cannot adequately convey all uncertainties and nuances of patient care.

show abstract

Comparison of the PRNT and an immune fluorescence assay in yellow fever vaccinees receiving immunosuppressive medication

Cited by 22 publications

References 19 publications

Inadvertent yellow fever vaccination of a patient with Crohn's disease treated with infliximab and methotrexate

Inadvertent yellow fever vaccination of a patient with Crohn's disease treated with infliximab and methotrexate

Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases

2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases

Contact Info

Product

Resources

About